Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection
Inflammatory Bowel Diseases · 01.06.2023 · 29 (6) · 888-897
DOI: 10.1093/ibd/izac158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 29.07.2022. Verfasst von Jordan E Axelrad und 16 weiteren Autor:innen. Beteiligte Einrichtung: Divison of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Crohn Disease. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Crohn's and Colitis Foundation, NIH.
Abstract (Originalsprache)
Background
Postoperative recurrence (POR) of Crohn’s disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR).
Methods
We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (≥ i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab).
Results
We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis.
Conclusion
Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divison of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
- Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.
- Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA.
- Divison of Gastroenterology, Department of Medicine, University of Vermont Larner College of Medicine, Burlington, VT, USA.
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
- Department of Colorectal Surgery, Cleveland Clinic, Cleveland, OH, USA.
ORCID-Profile: Jordan E Axelrad, Salam P Bachour, Stefan D Holubar, Amy L Lightner, Edward L Barnes, Miguel Regueiro
Förderung
- NIDDK NIH HHS
- Crohn's and Colitis Foundation
- NIH
- NIDDK
Zitieren
APA
Axelrad, J. E., Li, T., Bachour, S. P., Nakamura, T. I., Shah, R., Sachs, M. C., Chang, S., Hudesman, D. P., Holubar, S. D., Lightner, A. L., Barnes, E. L., Cohen, B. L., Rieder, F., Esen, E., Remzi, F., Regueiro, M., & Click, B. (2023). Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection. Inflammatory Bowel Diseases, 29(6), 888-897. https://doi.org/10.1093/ibd/izac158
Vancouver
Axelrad JE, Li T, Bachour SP, Nakamura TI, Shah R, Sachs MC, et al. Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection. Inflammatory Bowel Diseases. 2023;29(6):888-897. doi:10.1093/ibd/izac158
BibTeX
@article{Axelrad2023,
author = {Axelrad, Jordan E and Li, Terry and Bachour, Salam P and Nakamura, Takahiro I and Shah, Ravi and Sachs, Michael C and Chang, Shannon and Hudesman, David P and Holubar, Stefan D and Lightner, Amy L and Barnes, Edward L and Cohen, Benjamin L and Rieder, Florian and Esen, Eren and Remzi, Feza and Regueiro, Miguel and Click, Benjamin},
title = {Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn’s Disease Following Ileocecal Resection},
journal = {Inflammatory Bowel Diseases},
year = {2023},
volume = {29},
number = {6},
pages = {888--897},
doi = {10.1093/ibd/izac158}
}
EUVIMED